Role of mitochondrial DNA variants in the development of fragile X-associated tremor/ataxia syndrome.


Journal

Mitochondrion
ISSN: 1872-8278
Titre abrégé: Mitochondrion
Pays: Netherlands
ID NLM: 100968751

Informations de publication

Date de publication:
05 2020
Historique:
received: 12 07 2019
revised: 08 01 2020
accepted: 09 03 2020
pubmed: 17 3 2020
medline: 8 6 2021
entrez: 17 3 2020
Statut: ppublish

Résumé

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that appears in at least one-third of adult carriers of FMR1 premutation. Several studies have shown that mitochondrial dysfunction may play a role in neurodegenerative disorders. In order to assess whether mitochondrial DNA variants are involved in the risk of developing FXTAS we evaluated the frequency of mitochondrial haplogroups in 132 unrelated Spanish FMR1 premutation carriers. In addition, the entire mitogenome of 26 FMR1 premutation carriers was sequenced using massively parallel sequencing technologies to analyze mitochondrial DNA variants. Statistical analyses reveal a significant difference in the frequency of T haplogroup. Data analysis of mitochondrial DNA sequences evidence an association between FXTAS and the burden of heteroplasmic variants as well as their distribution. Our results suggest that haplogroup T might be a potential protective factor for FXTAS and that FXTAS individuals accumulate higher rates of heteroplasmic variants in compromised regions of the mitochondrial genome. These results may explain, in part, the role of mitochondrial DNA in the development of FXTAS.

Identifiants

pubmed: 32173566
pii: S1567-7249(19)30185-0
doi: 10.1016/j.mito.2020.03.004
pii:
doi:

Substances chimiques

DNA, Mitochondrial 0
FMR1 protein, human 0
Fragile X Mental Retardation Protein 139135-51-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

157-162

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Maria Isabel Alvarez-Mora (MI)

Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain.

Cristina Santos (C)

Unitat d'Antropologia Biològica, Departament de Biologia Animal, Biologia Vegetal i Ecologia, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.

Lidia Carreño-Gago (L)

CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain; Departament de Patología Mitocondrial i Neuromuscular, Hospital Universitari Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.

Irene Madrigal (I)

Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain.

Maria Isabel Tejada (MI)

CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain; Biocruces Health Research Institute, Barakaldo-Bizkaia, Spain; Molecular Genetics Laboratory, Genetics Service, Cruces University Hospital, Barakaldo, Spain.

Francisco Martinez (F)

Genetics Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain.

Silvia Izquierdo-Alvarez (S)

Genetics Department of Clinical Biochemistry Service, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Elena Garcia-Arumi (E)

CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain; Departament de Patología Mitocondrial i Neuromuscular, Hospital Universitari Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain; Àrea de Genètica Clínica i Molecular, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Montserrat Mila (M)

Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain.

Laia Rodriguez-Revenga (L)

Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBER of Rare Diseases, Instiuto de Salud Carlos III, Spain. Electronic address: lbodi@clinic.ub.es.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH